Market Cap$81.41B
P/E18.07x
PEG Ratio1.36
Div yield0.46%
Beta0.13
REGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-5.24%
Price vs S&P 500 (4W)0.39%
PEG Ratio1.36
VGM Score60.26
P/E Ratio (Annual)18.07x
Indicated Dividend Yield (Annual)0.46%
REGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $10.21 | $14.29 | +39.99%(+$4.08) | |
| Q1 2026 | $8.90 | $9.47 | +6.38%(+$0.57) | |
| Q4 2025 | $10.75 | $11.44 | +6.38%(+$0.69) | |
| Q3 2025 | $9.64 | $11.83 | +22.66%(+$2.19) | |
| Q2 2025 | $8.44 | $12.89 | +52.72%(+$4.45) |
REGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.95
3.95
3.92
3.89
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
REGNRegeneron Pharmaceuticals Inc | C | C | A | 5.2x | 9.3% | 86.0% | 6.3% | $790.74 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers and commercializes biopharmaceutical products across ophthalmology, immunology, cardiovascular disease, oncology, and rheumatology, with marketed drugs including Eylea HD, Dupixent, Praluent, Libtayo, and Kevzara. The company develops monoclonal and bispecific antibodies independently and through collaborations, including a partnership with Sanofi. Regeneron is advancing next-generation therapies through early-stage partnerships in RNAi and CRISPR-based gene editing.